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Background. as it is established that diabetes mellitus causes metabolic disturbances of all types (first of 
all because of carbohydrate metabolism), affection of blood vessels, nerves, different organs and tissues. However, 
the influence of dM on the level of microelements is still not investigated enough. despite the sufficient variety 
of medicaments, compensation of diabetes mellitus is achieved in less than 30% of patients. For this reason, the 
search of new ways of treatment which are aimed at the improvement of carbohydrate metabolism is an urgent 
issue. 
Objective. The research was aimed to reveal the deficiency of 25­hydroxyvitamin D3 [25(OH)D3] and its 
correlation with carbohydrate metabolism.
Methods. Thirty five patients with diabetes mellitus Type 2 aged 55–74 with illness duration 2–4 years 
were examined. The control group included 35 healthy people of the same age and sex. Levels of 25-hydroxyvitamin 
D3 [25(OH)D3] were tested by means of radioimmunoassay. The level of glycated haemoglobin was tested by 
means of liquid chromatography.
Results. Correlation of the level of vitamin D with the degree of diabetes mellitus Type 2 compensation has 
been detected.
Conclusions. A clear tendency to the improvement of diabetes mellitus Type 2 compensation after medication 
correction with vitamin D was evidenced. 
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Introduction
Diabetes mellitus (DM) — is a non-infectious 
epidemic of XXI century. According to World 
statistics data, the amount of people with DM 
doubles every 13-15 years. Today there are 415 
million patients with DM in the world, and their 
amount will increase to 642 million in 2040. New 
drugs do not contribute to the disease suppres-
sion, and the intensification of diagnostic 
criteria causes rapid increase in the number of 
patients. Mainly the increase of patients mainly 
with DM type 2.
Today, in Ukraine the DM compensation is 
unsatisfactory because the average rate of 
glycated haemoglobin (HbA1c) within DM type 
1 is about 9.0%, and within DM type 2 – about 
8.5% [2]. In our day, it is ultimately important 
to search for pathogenetic links for efficiency 
of patients’ with DM treatment improvement.
So, much attention is paid to the study of 
vitamin D influence on different organs and 
systems in case of different diseases, DM as well. 
Recently scientists began to study the influence 
of vitamin D on the course of DM type 2 [4,5,6,7]. 
Some authors suggest, that vitamin D 
insufficiency is a risk factor of DM type 2 [6], 
other — that vitamin D supports glucose ho meo-
 stasis and is inversely proportional to the level 
of glycated haemoglobin in DM type 2 [8]. Also 
there is a suggestion, that an adequate vitamin 
D intake may be connected with lower risk of a 
gestational diabetes mellitus develop ment [9].
Physiological effects of vitamin D is poly-
hedral, it is difficult to select some less signi­
ficant factors. Vitamin D influences the phos­
phorus­calcium exchange: calcium and other 
microelements cannot be absorbed in its defi­
ciency. Activity of vitamin D is directly connected 
with many physiological processes in organism, 
in particular with vitamin e admission, liver 
function and function of intestine, lipid meta-
bolism. vitamin D is necessary for providing 
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normal functioning of immune system, repro-
ductive and sexual health, and hematopoietic 
system. That is why, cholecalciferol and its 
active metabolites is applied for treatment of 
immunodeficiency, anaemia, various patholo­
gical conditions of liver, gastrointestinal tract, 
diabetes, cardiovascular system, tuberculosis, 
cancers of breast and bowel, prostate, locally 
for the treatment of psoriasis.
According to statistical data [3], among all 
residents of Ukraine, only 4.6% of the examined 
people had normal level of vitamin D, 13.6% of 
the population was diagnosed with its failure, 
and in 81.8% of residents the deficit was 
pronounced.
However, how the level of vitamin D can 
change, and whether its change can influence 
on indicators of compensation for diabetes 
remains poorly examined.
According to the literature [10], objective 
criterion of vitamin D security, is the determi-
nation of 25-hydroxy vitamin D3 [25 (OH) D3] 
contents.
The study is aimed to reveal the deficiency 
of 25-hydroxy vitamin D3 and its cross-corre-
lation with glycated haemoglobin of patients 
with diabetes type 2.
Material and Methods
35 patients with diabetes mellitus type 2 
were examined, the individuals were aged from 
55 to 74, illness duration was 2–4 years. The 
control group included 35 healthy people of the 
same age and sex. The patients, who suffered 
from DM type 2, took oral hypoglycaemic drugs 
of biguanides in therapeutic doses (1000-2500 
mg daily). Additionally patients of both group 
received the drug Alpha D3 Teva, dose 1 mkg 
daily during 3 month. levels of 25-hydroxyvitamin 
D3 [25(OH)D3] were tested by means of radio-
immunoassay. The level of glycated haemo-
globin (HbA1c) was tested by means of liquid 
chromatography. 
The results of 25(OH)D3 and HbA1c were 
determined before the start of vitamin D taking 
and after 3 months of treatment with it.
Statistical evaluation of results was realized 
by methods of variation statistics with calcu-
lation of frequency performance indicators (P) 
and averages (the arithmetic mean X). Statistical 
significance of the result if compared the pa­
tient groups with the control one was evaluated 
using Student t-test. Regression analysis was 
used to determine the relationship between 
HbA1c levels and 25(OH)D3.
Results
After examination of patients with DM type 
2, all of them were identified either with the 
deficiency or insufficiency of vitamin D.
In accordance to classification (Holick MF et 
al) at the level of 25(OH)D3 50 nmol/l (20 ng/ml) 
to 75 nmol/l (30 ng/ml) D-vitamin failure is 
diagnosed, and decreased level of 25(OH)D3 
below 50 nmol/l (20 ng/ml) — vitamin D3 
deficiency.
We have found out that among 35 patients 
with DM type 2 nobody has normal level of 
vitamin D. 62.9% of patients were diagnosed 
with the deficiency of vitamin D (p<0.01), 
moreover in 22.7% of them good compensation 
was observed (p<0.01), in 31.8 % of the patients 
compensation was satisfactory (p<0.01), and in 
45.5% of the patients — unsatisfactory (p<0.01). 
Inverse correlation connection between the 
decrease level of vitamin D and increase level 
of glycated haemoglobin was detected (r=-0.40, 
p<0.05). We considered that compensation of 
DM was good when the level of glycated 
haemoglobin was <7.5%, satisfactory — at the 
level of glycated haemoglobin 7.5-8.5%, unsa-
tisfactory — when the level of glycated haemo-
globin was >8.5%. We justified the increased 
rate of glycated haemoglobin compensation 
because we examined patients of older age who 
were recommended to maintain higher 
indicators of HbA1c to avoid hypoglycaemia and 
brain hypoxia.
37,1% of the patients with DM type 2 
(p<0,01) suffered from vitamin D failure, 
moreover 61.5% of them had satisfactory 
compensation of diabetes (the level of glycated 
hemoglobin was 7.5-8.5%) (p<0,01), and 38.5% – 
unsatisfactory (the level of glycated haemo-
globin > 8.5%) (p<0,01). Inverse correlation 
between the decrease of vitamin D and increase 
of glycated haemoglobin was detected (r=-0.39, 
p<0.05). 
In the control group (without diabetes 
mellitus) there were only 25.7% of patients with 
a good level of vitamin D (p<0.01), 54.2% of 
people in the same group suffered from vitamin 
D insufficiency (p<0.01), and 20.1% of people 
were diagnosed with vitamin D deficiency 
(p<0.01). 
The low implementation of vitamin D for 
the older patients without diabetes may be 
associated with alimentary factor and age 
features of the body. 
In the control groups the level of glycated 
haemoglobin was 5.1±0.05% (p<0.01).
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The patients of both groups (except those 
with no deficiency) were provided with a drug 
Alpha D3 Teva – 1 mkg daily for three month to 
correct vitamin deficiency. After that, the levels 
of 25(OH)D3 and HbA1c were tested again.
The improvement of diabetes mellitus 
compensation is clearly stated for patients: 
decrease the number of patients with unsati-
sfactory compensation and increase of number 
of patients with good and satisfactory compen-
sation. 51.4% (p<0.01) of the patients were 
diagnosed with optimal levels of vitamin D and 
11.5% (p<0.01) had its failure. Inverse correlation 
connection between the increased level of 
vitamin D and decrease level of glycated 
haemoglobin was detected (r=-0.38, p<0.05).
We have established that a number of the 
patients with unsatisfactory compensation 
decreased, a number of the patients with 
satisfactory compensation increased, and 
patients with high compensation of diabetes 
was in evidence. After treatment with Alpha D3 
Teva, 34.2% out of 37.1% of the patients with 
vitamin D failure had normal vitamin D level 
(p<0.01), and 2.9% still had its insufficiency 
(p<0.01). Inverse correlation between the incre-
ased level of vitamin D and decreased level of 
glycated haemoglobin has been detected 
(r=-0.39, p<0.05).
In the control group, after three months of 
treatment with Alpha D3 Teva, 74.2% of the 
patients had normal vitamin D level (p<0.01), 
20% had its failure (p<0.01), 5.8% were diag-
nosed with the of vitamin D deficiency (p<0.01).
Discussion
Many authors consider the matter of vita-
min D deficiency, which is a predictor of various 
diseases and also promotes decom pensation 
of chronic diseases [11]. It is a topical issue in 
whole world and in Ukraine as well [12]. So, its 
deficiency correction should not seem less 
important. The drugs of cholecalciferoli are 
applied the most for its treatment [13], which, 
according to research literature, are first­line 
drugs that include ergocalciferol and structural 
analogue of vitamin D3-dyhidrotahisterol. The 
second-line drugs are calcitriol and alfacalcidol. 
As first­line drugs are exposed to 25­hydroxy­
lation in liver, afterwards are converted into 
active metabolites in kidneys, therefore, the 
metabolism of these drugs is decreased in 
elderly patients with different types of primary 
and secondary osteoporosis and then don’t 
have positive effect on bone system.
These defects are absent in the second-line 
drugs [14]. We suggest the drug alphacalcidol 
for vitamin D deficiency correction, because in 
our research we examined elderly patients.
Also, many patients suffer from osteopo-
rosis; in such case this drug is more efficient.
The efficiency of alphacalcidol (1 mkg per 
day) compared to the combination of vitamin 
D (880 MO per day) and calcium carbonate 
(1000 mg per day) for patients with postme-
nopausal osteoporosis and absence of vitamin 
D deficiency in blood plasma is presented in 
research literature.
In 12 months in the females, who took 
alfacalcidol, mineral density of lumbar bone 
was increased by 2.33% (from base level) and 
in 18 months by 2.87% (p<0.001), and in the 
group of patients, who received vitamin D and 
Ca — only by 0.7% [15].
There are various conclusions on calcitriol 
efficacy. Some researches proved significant 
Figure 1. The levels of glycated haemoglobin of the patients 
with diabetes mellitus type 2, who were diagnosed with 
Vitamin D deficiency (before and after treatment with Alpha 
D3 Teva).
Figure 2. The levels of glycated haemoglobin of the patients 
with diabetes mellitus type 2, who were diagnosed with 
vitamin D failure (before and after treatment with Alpha 
D3 Teva).
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effect of vitamin D on mineral density of bone 
for patients with postmenopausal osteoporosis 
[16, 17], others stated that such outcome was 
not obtained that may be associated with low 
doses [18].
Thus, we can argue that the drug alphacal-
cidol can be recommended for patients with 
vitamin D deficiency, diabetes type 2 and age­
related osteoporosis.
Conclusions
A clear tendency to the improvement of 
diabetes mellitus type 2 compensation after 
medication correction with vitamin D was 
evidenced. 
So, by correcting vitamin D deficiency the 
compensation of diabetes is improved.
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